Item 7.01. Regulation FD Disclosure. On June 30, 2025, Arcturus Therapeutics Holdings Inc. (the “ Company” or “ Arcturus”) issued a press release, announcing positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crises (the “ Release”). The Company also provided a corporate presentation regarding ARCT-810 via webcast, which is available on the Company’s website (the “ Presentation”). A copy of the Release is furnished herewith as Exhibit 99.1 and incorporated into this Item 7.01 by reference. A copy of the Presentation is furnished herewith as Exhibit 99.2 and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K, and Exhibit 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, the Release attached as Exhibit 99.1, and in the Presentation attached as Exhibit 99.2 to this Current Report on Form 8-K, shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated June 30, 2025 99.2 Presentation dated June 30, 2025 ───────────────────────────────────────────────────────────────────────────────── 104 Cover Page to this Current Report on Form 8-K in Inline XBRL SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: June 30, 2025 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer